NCT05590884

Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age

Gadopiclenol Pharmacokinetics, Safety and Efficacy in Pediatric Patients < 2 Years of Age

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Guerbet · Industry
• Sex: All
• Age: 23 Months
• Healthy volunteers: Not accepted

Summary

This Phase II open-label, uncontrolled, multicenter trial is designed to investigate the pharmacokinetic (PK) profile of gadopiclenol in plasma, in pediatric patients aged up to 23 months inclusive (term neonates or preterm infants after the neonatal period), using a population PK approach. Primary objective is to evaluate the PK profile of gadopiclenol in plasma following single intravenous injection of 0.05 mmol/kg body weight (BW) in pediatric population aged up to 23 months (inclusive) scheduled for a contrast-enhanced MRI examination of any body region including central nervous system (CNS).

Detailed description

Three age groups are defined: * Group 1: patients aged 3 to 23 months (inclusive) * Group 2: patients aged 28 days to less than 3 months; * Group 3: patients aged from birth to 27 days (term newborns). At study set-up, the inclusions started with the oldest patients in group 1 and using an age-down staggered approach. The decision to start the inclusions in group 2 was taken by the Trial Safety Review Board based on safety assessment over one-day period after injection of the first 13 patients in group 1. According to the protocol version 4 (amendments 2 \& 3), the age-down staggered approach was discontinued to allow the inclusions in Group 3 (patients aged from birth to 27 days), simultaneously to inclusions in group 1 and group 2. A total of 3 blood samples per patient were taken post-injection for PK analysis.

Conditions

• Central Nervous System Diseases
• Pediatric Disorder
• Body Indication

Interventions

Type	Name	Description
DRUG	Gadopiclenol	Patients will receive a single dose of gadopiclenol calculated according to their BW on the day of MRI examination. Gadopiclenol will be administered at a dose of 0.05 mmol/kg BW (0.1 mL/kg BW).

Timeline

• Start date: 2022-09-21
• Primary completion: 2024-09-30
• Completion: 2024-09-30
• First posted: 2022-10-21
• Last updated: 2025-10-28
• Results posted: 2025-10-28

Locations

11 sites across 3 countries: United States, Hungary, Poland

Regulatory

• FDA-regulated drug study